{
    "Clinical Trial ID": "NCT00190671",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Pemetrexed 600mg/m2",
        "  Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles",
        "INTERVENTION 2: ",
        "  Pemetrexed 1800mg/m2",
        "  Pemetrexed: 1800 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles"
    ],
    "Eligibility": [
        "Inclusion Criteria: - You must be female and at least 18 years old. - You must have been diagnosed with breast cancer. - Your pre-study lab tests are within study requirements. - You must be willing to take folic acid and vitamin B12. Exclusion Criteria: - You are pregnant or breastfeeding. - You have another illness that your doctor thinks would make you unable to participate. - You are currently taking aspirin or aspirin-like medicine and are unable to stop for a few days during each cycle of therapy."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Best Tumor Response",
        "  Tumor response was assessed using radiological imaging, which was repeated every 6 weeks prior to every other cycle. Confirmation of response was to occur no less than 4 weeks (28 days) after the first evidence of response.",
        "  Time frame: baseline to measured progressive disease",
        "Results 1: ",
        "  Arm/Group Title: Pemetrexed 600mg/m2",
        "  Arm/Group Description: Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles",
        "  Overall Number of Participants Analyzed: 42",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 8",
        "  Stable Disease: 18",
        "  Progressive Disease: 13",
        "  Unknown: 3",
        "Not Assessed: 0",
        "Results 2: ",
        "  Arm/Group Title: Pemetrexed 1800mg/m2",
        "  Arm/Group Description: Pemetrexed: 1800 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles",
        "  Overall Number of Participants Analyzed: 61",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 20",
        "  Stable Disease: 26",
        "  Progressive Disease: 8",
        "  Unknown: 5",
        "Not Assessed: 2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6",
        "  Agranulocytosis 0/42 (0.00%)",
        "  Anaemia 2/42 (4.76%)",
        "  Febrile neutropenia 1/42 (2.38%)",
        "  Leukopenia 0/42 (0.00%)",
        "  Neutropenia 1/42 (2.38%)",
        "  Thrombocytopenia 1/42 (2.38%)",
        "  Cardio-respiratory arrest 0/42 (0.00%)",
        "  Pericardial effusion 1/42 (2.38%)",
        "  Gastric ulcer haemorrhage 0/42 (0.00%)",
        "  Melaena 0/42 (0.00%)",
        "  Fatigue 1/42 (2.38%)",
        "  Multi-organ failure 0/42 (0.00%)",
        "Adverse Events 2:",
        "  Total: 13",
        "  Agranulocytosis 1/61 (1.64%)",
        "  Anaemia 1/61 (1.64%)",
        "  Febrile neutropenia 0/61 (0.00%)",
        "  Leukopenia 2/61 (3.28%)",
        "  Neutropenia 2/61 (3.28%)",
        "  Thrombocytopenia 1/61 (1.64%)",
        "  Cardio-respiratory arrest 1/61 (1.64%)",
        "  Pericardial effusion 0/61 (0.00%)",
        "  Gastric ulcer haemorrhage 1/61 (1.64%)",
        "  Melaena 1/61 (1.64%)",
        "  Fatigue 1/61 (1.64%)",
        "  Multi-organ failure 1/61 (1.64%)"
    ]
}